Paola Marignani PhD, MBA
Professor Dalhousie University, Faculty of Medicine
- Halifax, Canada Area NS
Dr. Paola Marignani is a scientist dedicated to developing personalized precision medicine that will improve human health.
Social
Areas of Expertise
Education
Ivey School of Business
MBA
Executive MBA
2013
Ontario Cancer Institute
Cancer
2002
Samuel Lunenfeld Research Institute- Mount Sinai Hospital
Mass Spectrometry
2001
Harvard Division of Signal Transduction
Fellow
2000
McMaster University
PhD
Cell Biology
1997
Western University (UWO)
MSc Neuropathology
1992
University of Windsor
Honours BSC
Biology and Chemistry
1988
Languages
- English
- Italian
- French
- Swedish
Media Appearances
Novel drugs in the battle against breast cancer
Shedon McLeod Radio Show radio
An interview with Dr. Paola Marignani who discovered a new drug combination that stops HER2+ breast cancer from developing in mice re-engineered to develop breast cancer.
Promising new drugs in the battle against breast cancer
CTV tv
Promising new drugs have been discovered to be effective at halting HER2+ breast cancer in mice re-engineered to develop breast cancer. Dr. Paola Marignani and her team of scientists pre-clinically tested new drugs; AZD8055 and 2-DG. When administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.
Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
New Breast Cancer Treatment
Global News tv
Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.
Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
New Drug combination halts HER2+ breast cancer in mice engineered to develop cancer
Radio Canada radio
Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.
Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.
Low dose chronic exposure to chemical mixtures
CTV tv
Dr. Marignani, a member of the Halifax Project reports on how low-dose chronic exposure to common chemicals may contribute to the development of diseases.
House hold chemicals
Global News tv
Dr. Marignani and colleagues report on how low-dose exposure to common chemicals may contribute to the development of cancers and other diseases.
